Genetic variants of the sulfotransferase 1A1 and breast cancer risk

Breast Cancer Research and Treatment
Uwe LangsenlehnerHellmut Samonigg

Abstract

Sulfotransferase 1A1 (SULT1A1), also designated as phenol-preferring sulfotransferase, is involved in the bioactivation and detoxification of a variety of potential carcinogens, including iodothyronines, hydroxylated aromatic amines, and phenolic xenobiotics. A common arginine (R) to histidine (H) polymorphism at amino acid position 213 influences SULT1A1 activity and has been suggested as risk factor for a different types of cancers. To investigate the role of this polymorphism for breast cancer risk, SULT1A1 genotype was determined in 500 women with clinically verified breast cancer and 500 female age-matched healthy control subjects. Frequencies of heterozygous (controls: 42.5% patients: 50.2%) or homozygous (controls: 12.6%; patients: 9.4%) carriers of the 213H variant were not significantly different between groups. The SULT1A1 genotype was furthermore not associated with tumor size, histological grading, estrogen or progesterone receptor status and age at diagnosis. The SULT1A1 213H variant was associated with the presence of lymph node metastases (p = 0.002). We conclude that the SULT1A1 R213H polymorphism is not a general risk factor for breast cancer, but may be involved in lymph node metastazing in breast cancer patie...Continue Reading

References

Sep 1, 1992·Chemical Research in Toxicology·K el-Bayoumy
Apr 1, 1997·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·H Glatt
Jun 3, 2000·Annual Review of Pharmacology and Toxicology·K Nagata, Y Yamazoe
Jul 8, 2003·International Journal of Cancer. Journal International Du Cancer·Peter KripplHellmut Samonigg
Oct 24, 2003·Breast Cancer Research and Treatment·Uwe LangsenlehnerHellmut Samonigg
Nov 6, 2003·Naunyn-Schmiedeberg's Archives of Pharmacology·Hansruedi Glatt, Walter Meinl
Jan 2, 2004·Breast Cancer Research and Treatment·Peter KripplHellmut Samonigg

❮ Previous
Next ❯

Citations

Apr 1, 2006·Journal of Cancer Research and Clinical Oncology·Stefania BocciaGualtiero Ricciardi
Oct 24, 2006·Breast Cancer Research and Treatment·Armin GergerPeter Krippl
May 14, 2009·Breast Cancer Research and Treatment·Armin GergerUwe Langsenlehner
Dec 2, 2009·Breast Cancer Research and Treatment·Zhanwei WangWen-ming Chu
Nov 11, 2005·Breast Cancer Research : BCR·Ekaterina G ShatalovaRebecca L Blanchard
Mar 6, 2010·Journal of Cancer Research and Clinical Oncology·Gudrun KnechtelUwe Langsenlehner
May 20, 2009·Pharmacogenetics and Genomics·Michelle HildebrandtRuss B Altman
Dec 26, 2006·Human Molecular Genetics·Scott J HebbringStephen N Thibodeau

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.